You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
AstraZeneca
Johnson and Johnson
Harvard Business School
McKinsey

Last Updated: January 26, 2021

DrugPatentWatch Database Preview

Patent: 9,663,484

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,663,484
Title:Isoflavonoid compounds and methods for the treatment of cancer
Abstract: Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.
Inventor(s): Jeoffreys; George (Baulkham Hills, AU), Johnson; Alison (Drummoyne, AU), Heaton; Andrew (Alexandria, AU), Moreno; Ofir (Poway, CA)
Assignee: MEI PHARMA, INC. (San Diego, CA)
Application Number:13/881,609
Patent Claims:see list of patent claims

Details for Patent 9,663,484

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial MEI PHARMA, INC. (San Diego, CA) 2030-11-01 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial MEI PHARMA, INC. (San Diego, CA) 2030-11-01 RX search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 001 2004-02-26   Start Trial MEI PHARMA, INC. (San Diego, CA) 2030-11-01 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Start Trial MEI PHARMA, INC. (San Diego, CA) 2030-11-01 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

International Patent Family for US Patent 9,663,484

Country Patent Number Estimated Expiration
World Intellectual Property Organization (WIPO) 2012061409   Start Trial
World Intellectual Property Organization (WIPO) 2012061413   Start Trial
United States of America 10105346   Start Trial
United States of America 10369132   Start Trial
United States of America 2013273177   Start Trial
United States of America 2014234295   Start Trial
United States of America 2017246142   Start Trial
>Country >Patent Number >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Merck
Colorcon
Dow
McKesson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.